IGFBP4 and hydrops fetalis: In contemporary-treated STEMI patients, Stanniocalcin-2 and IGFBP-4 were strong predictors of mortality and HF readmission and may become valuable cardiovascular biomarkers, combined with traditional clinical predictors, for identifying high-risk STEMI patients.